-
NMPA Announcement on Adding the Medication Information for Children to the Package Inserts of Haloperidol Tablets and Other Varieties
2021-05-31
In order to better meet the clinical medication needs of children, upon the study and demonstration, package inserts of Haloperidol Tablets and other varieties may be added with the children users and dosage and usage for children according to the requirements.
-
NMPA Announcement on Implementing Relevant Matters of the Regulations for the Supervision and Administration of Medical Devices
2021-05-31
The revised Regulations for the Supervision and Administration of Medical Devices will be implemented as of June 1, 2021.
-
NMPA Announcement on the Cancellation of Registration Certificates for 283 Drugs including Megestrol Acetate Dispersible Tablets
2021-05-24
According to the Regulations for the Implementation of the Drug Administration Law of the People's Republic of China and the Provisions for Drug Registration, NMPA has decided to cancel the registration certificate of 283 drugs including Megestrol Acetate Dispersible Tablets.
-
NMPA Announcement on Issuing the Working Procedures for Dynamic Adjustment of Classification Catalogue for Medical Devices
2021-05-08
NMPA has organized to formulate the Working Procedures for Dynamic Adjustment of Classification Catalogue for Medical Devices, which was issued on April 27.
-
NMPA CDE Announcement on Issuing the Guidance for Clinical Trials of Biosimilars of Tocilizumab Injection
2021-04-21
CDE has organized to formulate the Guidance for Clinical Trials of Biosimilars of Tocilizumab Injection, which was issued for implementation on April 21 upon review and approval by NMPA.
-
NMPA CDE Announcement on Issuing the Guidance for Clinical Trials of Biosimilars of Pertuzumab Injection
2021-04-21
CDE has organized to formulate the Guidance for Clinical Trials of Biosimilars of Pertuzumab Injection, which was issued for implementation on April 21 upon review and approval by NMPA.
